Objective: The objective of this study was to measure the prevalence of Chlamydia trachomatis (CT) infection among men in clinical and nonclinical settings across the United States.
IN THE UNITED STATES, resources to detect and treat Chlamydia trachomatis (CT) infections have been directed primarily to screening and treating women, who are at risk for serious sequelae from CT infection, which include pelvic inflammatory disease, ectopic pregnancy, and infertility. Annual CT screening for sexually active 15-to 25-year-old women is recommended by the Centers for Disease Control and Prevention and other agencies. 1 Among men, sequelae from untreated CT infection appear modest, although some sequelae have been suggested by recent research. 2 Testing males with symptoms of urethritis for CT and treating those found to be infected has long been recommended; however, without evidence that screening asymptomatic men is an effective means of reducing CT disease and sequelae among women, public health agencies have been reluctant to recommend and direct resources to male screening. Because asymptomatic men may be an important reservoir of chlamydial infection, 3 and the source of many infections and associated sequelae among women, the prevalence of CT infection among asymptomatic men accessible for screening will be a key determinant of the value of a male screening program to women's health.
To date, there have been few reports of large-scale U.S. programs aimed at screening asymptomatic men. 4, 5 The availability and widespread use of urine-based nucleic-acid amplification techniques for the detection of CT has obviated the need to obtain invasive samples and has allowed screening in nonclinical settings where populations at risk for CT are found. 6, 7 To measure the prevalence of CT among men in a variety of venues, we implemented a broad-based male CT testing program using urine testing in 4 U.S. cities. Between October 1999 and April 2003, we tested over 23,000 symptomatic and asymptomatic men for CT in Baltimore, Denver, San Francisco, and Seattle.
Materials and Methods
Urine-based testing for CT was offered to males in juvenile or adult detention facilities, and to males attending adolescent or adult primary care clinics, high school health clinics, college clinics and health fairs, street outreach programs, communitybased organizations, or a drug rehabilitation program. For all men, a brief intake form was completed, which included demographic data and questions related to sexual health. Urine specimens were tested for CT using a nucleic acid amplification test (LCR [Abbott Laboratories, Abbott Park, IL], PCR [Roche Diagnostic Systems, Indianapolis, IN], or SDA [Becton Dickinson Diagnostic Systems, Sparks, MD]). Although the type of test used varied between cities, testing was performed at a single laboratory in each city over the period of study. CT-infected men were notified and treated, and efforts were made to notify their sex partners for testing and treatment.
Because some men were tested more than once over the 3 1 ⁄2-year study period, we selected the first testing episode for each individual, and estimated CT prevalence for the entire interval, limiting the analysis to men tested in types of venues where at least 50 men were tested over the study period. Men who reported discharge or dysuria on the intake form were considered symptomatic. Adolescent or adult primary care, college and school clinics were defined as clinical settings. Patient and venue characteristics were described by univariate analyses; associations with chlamydial infection were assessed using bivariate techniques; P values Ͻ0.05 were considered statistically significant. All analyses were done using SAS (Statistical Analysis Software version 8; SAS Institute Inc., Cary, NC).
Results
A total of 23,507 men were tested at least once at over 50 different venues in the 4 cities ( Table 1 ). The median age was 21 years. Forty percent of men were of non-Hispanic black race/ ethnicity, 25% Hispanic, 19% non-Hispanic white, 7% Asian/ Pacific Islanders, and 10% other races. The majority of men tested for CT (96%) were asymptomatic. Men in Baltimore, Denver, and Seattle provided information regarding sex partners, condom use, and history of CT infection. Overall, 65% of men (4384 of 6760) reported 1 or no sex partner in the 60 days before testing.
The overall CT prevalence was 7% and varied by city (Seattle, 1%; San Francisco, 5%; Denver, 10%; Baltimore, 12%). Prevalence was highest among men aged 15 to 19 years (8%) and 20 to 24 years (9%). CT prevalence was substantially higher among symptomatic men (22%) than among asymptomatic men (6%). The prevalence of infection was not significantly higher among men with multiple sex partners compared with men with only 1 sex partner (11% vs. 12%, P ϭ 0.26) or those who had not used a condom at last sex with a casual partner (13% vs. 11%, P ϭ 0.07); however, CT prevalence was significantly higher among men who had acquired a new sex partner in the past 2 months (12% vs. 9%, P Ͻ0.001), those who had not used a condom at last sex with a main partner (14% vs. 9%, P Ͻ0.001), and those who had a history of CT infection (14% vs. 9%, P Ͻ0.001).
In all 4 cities, urine-based testing was conducted in at least 1 type of detention setting, either juvenile (Denver, San Francisco, and Seattle) or adult detention (Baltimore, Denver, and San Francisco) ( Table 2) . Approximately half of all testing (51%; 11,979 of 23,507) occurred in adult detention, the majority of which (85%; 10,138 of 11,979) was conducted in the San Francisco jail system. Testing in juvenile detention accounted for 18% of testing overall. Fifty percent of infections detected over the study period (781 of 1548) were detected in adult detention settings and 16% in juvenile detention. School clinics accounted for 7% of testing (10% of infections detected); street outreach, 8% of testing (4% of infections); adolescent and adult primary care, 8% of testing (15% of infections); and all others, 7% of testing (5% of infections).
Overall, the proportion of men with symptoms was significantly higher at adolescent primary care clinics (18%) and adult primary care clinics (19%) than at other types of venues (P Ͻ0.001), where the proportion of men symptomatic ranged from 0% to 6%. Overall, CT prevalence was significantly higher among men attending adolescent primary care venues than among men in other settings. In Baltimore, the prevalence among asymptomatic men attending adolescent primary care (20%) was significantly higher than the overall prevalence at other venues in that city, whereas the prevalence among asymptomatic men tested in adolescent primary care in Denver (13%) and San Francisco (7%) was similar to the overall prevalence (symptomatic and asymptomatic men together) in several other venues in those cities. In Baltimore and San Francisco, the overall prevalence in school clinics was the same or similar to that measured in adult detention. In Baltimore, Denver, and San Francisco, the prevalence in most venues was markedly higher among symptomatic men compared with asymptomatic men; however, in Seattle, the prevalence was low in all venues, and did not differ for asymptomatic and symptomatic men.
Discussion
With a prevalence of 7% overall, and 6% among asymptomatic men, the prevalence of CT among men in these 4 U.S. cities is comparable to, or somewhat higher than has been reported previ- 8 The prevalence of CT infection was less than 5% in all 3 surveys. In this study, the prevalence varied widely across the cities. This is, in part, the result of the different types of venue where testing was conducted in each city. Differences in prevalence across cities may also reflect geographic differences in disease burden, because chlamydia case rates among women vary by regions of the United States, 9 and the disease burden among men in the 4 cities (Baltimore, Denver, San Francisco, and Seattle) mirrors the rank order of chlamydial disease rates for women in the same 4 cities.
Not surprisingly, the prevalence of CT infection was higher among symptomatic men (22%) than among asymptomatic men (6%) in virtually all types of venues. However, almost half of symptomatic infections (83 of 203; 41%) were detected among men tested in nonclinical settings. Moreover, only 21% of the 1345 asymptomatic infections were detected in clinical settings. Most of the infections detected by screening would not have been diagnosed without a broad-based screening program, which included nonclinical venues.
Because of wide variation in prevalence at different venues, sexually transmitted disease programs undertaking male screening should identify local venues where men can be feasibly screened and determine the likely yield of screening in those settings. Age criteria may be useful to target screening activities in venues that include men across a broad age range. However, programs contemplating male screening should realize that local CT screening coverage among women may be suboptimal; despite recommendations for annual screening of sexually active 15-to 25-year-old women, at most, only two thirds of sexually active 15-to 19-yearold females in the United States are screened annually for CT. 10 Decisions regarding female screening have been greatly influenced by cost-effectiveness analyses showing that it is cost saving to screen women when CT prevalence is above certain levels. 11 Cost-effectiveness analyses of male screening have used the number of sequelae averted among female partners as key parameters in establishing the cost savings of that intervention. 12, 13 Future cost-effectiveness analyses should also compare the relative value of screening men to reduce sequelae among women with screening a larger proportion of at-risk women.
